Future Medicine

SHERPA: White

People

  1. Tap
    Tap
  2. D'Angelo
    D'Angelo
  3. Gounder
    Gounder
  4. Chi
    Chi
  5. Healey
    Healey

Groups

  1. Department of Medicine (9)
  2. Sarcoma Service (9)
  3. Solid Tumor Oncology Division (9)
  4. Hematologic Malignancies, Division of (2)
  5. GSK Faculty (1)
  6. Human Oncology and Pathogenesis Program (1)
  7. Orthopaedic Service (1)
  8. Sarcoma Surgeons (1)
  9. Surgery (1)
  10. Tow Center for Developmental Oncology (TCDO) (1)
Search Within
  1. "Sarcoma Service"
Formats
  1. Journal Article (7)
  2. Editorial (1)
  3. Review (1)
Groups
  1. Department of Medicine (9)
  2. Sarcoma Service (9)
  3. Solid Tumor Oncology Division (9)
  4. Hematologic Malignancies, Division of (2)
  5. GSK Faculty (1)
  6. Human Oncology and Pathogenesis Program (1)

More Groups

People
  1. William Tap (5)
  2. Mrinal Gounder (2)
  3. Sandra D'Angelo (2)
  4. John Healey (1)
  5. Ping Chi (1)
Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2022 (1)
  4. 2021 (1)
  5. 2020 (2)
  6. 2016 (1)
Publications
  1. Future Oncology (8)
  2. Immunotherapy (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Localized and diffuse tenosynovial giant cell tumor: Real-world results from a patient observational registry
    Journal Article

    Stern, S.; McKenzie, P. F.; Bernthal, N.; O’Neill, S.; Palmerini, E.; Randall, R. L.; Tap, W.; Scharschmidt, T.; Rothschild, S.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • A study to learn if nirogacestat works and is safe for adult participants with desmoid tumors: A plain language summary of the DeFi study
    Editorial

    Kasper, B.; Whiting, J.; Lawson, D.; Portnoy, M.; Schuster, K.; Baumgarten, C.; Ratan, R.; Lim, A.; Cho, S.; Kummar, S.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • The INSIGHT study: A randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations
    Journal Article

    George, S.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Gelderblom, H.; Zalcberg, J. R.; Reichmann, W.; Sprott, K.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • The MOTION study: A randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor
    Journal Article

    Tap, W. D.; Sharma, M. G.; Vallee, M.; Smith, B. D.; Sherman, M. L.; Ruiz-Soto, R.; van de Sande, M.; Randall, R. L.; Bernthal, N. M.; Gelderblom, H.
    Future Oncology (2024)

    Fulltext@MSK | Save
  • CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden
    Journal Article

    Peterfy, C.; Chen, Y.; Countryman, P.; Chmielowski, B.; Anthony, S. P.; Healey, J. H.; Wainberg, Z. A.; Cohn, A. L.; Shapiro, G. I.; Keedy, V. L.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
    Journal Article

    Gounder, M.; Abdul Razak, A. R.; Gilligan, A. M.; Leong, H.; Ma, X.; Somaiah, N.; Chawla, S. P.; Martin-Broto, J.; Grignani, G.; Schuetze, S. M.; more...
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
    Journal Article

    Bharmal, M.; Nolte, S.; Lebbé, C.; Mortier, L.; Brohl, A. S.; Fazio, N.; Grob, J. J.; Pusceddu, S.; Hanna, G. J.; Hassel, J. C.; more...
    Future Oncology (2020)

    Fulltext@MSK | Save
  • ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)
    Review

    Tap, W.
    Future Oncology (2020)

    Fulltext@MSK | Save
  • Current status of engineered T-cell therapy for synovial sarcoma
    Journal Article

    Dallos, M.; Tap, W. D.; D'Angelo, S. P.
    Immunotherapy (2016)

    Fulltext@MSK | Save

    • Future Medicine – authorized name for: